BTMD - NASDAQ
biote Corp.
$2.11
+5.5%biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.
At a Glance
Live Snapshotbiote Corp. Management Team
Dr. Cory Rice D.O.
Chief Clinical Advisor & Member of Medical Advisory Board
Mr. Richard Kevin Key
Chief Digital Officer
Mr. Bret Christensen
Chief Executive Officer & Director
Mr. Robert C. Peterson
Chief Financial Officer
Compensation
$590,962
Mr. John J. Olsen
Chief Information Officer
Mr. Joel Pickering
Chief Marketing Officer
Mr. James Elliott Gibbs II
Chief People Officer
Mr. Marc D. Beer
Executive Chairman
Compensation
$694,579
Mr. Jade Beutler
Head of Nutraceuticals
Ms. Mary Elizabeth Conlon
Vice President of Business Development, General Counsel & Corporate Secretary
Compensation
$552,360
biote Corp. Insider Positioning
During the last 12 months, insiders have purchased $591K worth of BTMD shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
150.4K
591.23K
0
0.00
+591K
+$591K
Top Buyers
Barrera Richard R
Director, 10 Percent Owner:
$591K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $591K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
1 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Unanimous insider buying: Zero selling combined with active buying is rare and typically very bullish. Insiders appear to see significant upside with limited downside risk.
SEC Filings
BTMD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 02, 2026 | May 12, 2026 | 2026 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.